Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.

Shanghai, China – October 10, 2025 – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced the appointment of Mr. Yifang Wu as chairman of the Board, along with other changes to the Board of Directors, as part of a leadership transition to further strengthen the Company. Mr. Wu has also been appointed as the Chairman of the Nomination Committee and a member of the Remuneration Committee. Mr. Wu has more than 35 years of experience in the biopharmaceutical industry and currently serves as an executive operating partner of CBC Group, a substantial shareholder of the Company. Mr. Wei Fu has been re-designated as a Non-Executive Director of the Company and stepped down as chairman of the Board. In recognition of his invaluable contributions and dedication during his tenure of office as Executive Director and Chairman, Mr. Fu has been appointed as Honorary Chairman of the Board to continue providing guidance and strategic support to the Company. Mr. Honggang Feng has resigned as a Non-Executive Director of the Company. Mr. Wu brings over three decades of unparalleled expertise in the pharmaceutical industry. Prior to joining the Company, he served as Executive President of Fosun International and was Chairman & CEO of Fosun Pharma for nearly a decade. During his tenure, he, as the core member of the management team, spearheaded Fosun Pharma’s transformation into a global leader, notably securing BioNTech’s mRNA technology for Greater China during the early stages of the pandemic. Mr. Wu also co-founded Wanbang Biopharmaceuticals and led the company as its Chairman & CEO, establishing a strong foundation in biopharmaceutical innovation. Mr. Wu obtained an Executive Master of Business Administration (EMBA) from Saint Joseph’s University in the United States in 2005. “We are pleased to welcome Mr. Wu as our new Chairman. His extensive industry experience and proven track record will bring valuable insights and momentum to our strategic growth,” said Rogers Yongqing Luo, CEO and Executive Director of Everest Medicines, “Under Mr. Wei Fu’s leadership, Everest Medicines has made remarkable progress in advancing its ‘dual-engine’ strategy and positioning the Company to become a leading global biopharmaceutical company by 2030. Building on this strong foundation, we are confident that, together with Mr. Wu, we will continue to drive the R&D and commercialization of innovative therapies, address unmet medical needs in China and beyond, and strengthen Everest’s position as a globally competitive biopharmaceutical company.” “I am deeply honored to join Everest Medicines. I would like to express my gratitude to Mr. Wei Fu for his visionary leadership and strategic foresight, which have been instrumental in the Company’s success,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines, “Under the leadership of Mr. Fu and Mr. Rogers Luo, Everest Medicines has achieved remarkable growth. I look forward to working closely with the Board and this exceptional management team to further strengthen the Company’s global presence and sustainable growth, by providing guidance to the senior management, and overseeing key initiatives in strategic transactions, R&D strategy, and stakeholder engagement, to achieve the goal of establishing Everest Medicines as a leading international biopharmaceutical company and delivering long-term value to our shareholders, employees, and partners." “CBC Group remains committed as the major shareholder in Everest through the Chairman transition. I am proud of what the Company has accomplished and am fully confident that, under Mr. Wu and Rogers’ leadership and execution, Everest will continue to scale globally and realize its long-term vision,” said Fu Wei, Honorary Chairman of the Board of the Company, and CEO of CBC Group. “Mr. Wu’s proven track record of transforming companies into global powerhouses and his strategic foresight will be invaluable as we continue to advance healthcare solutions globally. I look forward to supporting the Company as Honorary Chairman as it embarks on this next chapter of growth.” About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- In a world where diabetes is a growing concern, the latest research report, "Global Diabetes Devices and Therapeutics Business Investment Opportunities" added to ResearchAndMarkets.com's offering, comes as a beacon of hope and knowledge. November marks diabetes awareness month, and with the International Diabetes Federation projecting a staggering 51% increase in the number of people living with diabetes by 2045, the Global Diabetes report is not just a resource; it's a necessity for entrepreneurs and managers seeking investment opportunities in the diabetes care industry. The advanced diabetes care devices market is rapidly expanding, set to reach sales of $33.4 billion by 2030, with a compound annual growth rate (CAGR) of 6.34% over the period, according to GlobalData forecasts. The prevalence of diabetes, coupled with growing consumer awareness of technological advancements, has fueled this demand. The diabetes report delves deep into this thriving market, providing invaluable insights into the latest innovations and investment avenues. Effective diabetes management is vital in preventing complications, including heart disease, kidney disease, blindness, and amputations, all of which can result from elevated blood glucose levels. This report offers a comprehensive evaluation of the present market landscape, focusing on prospective growth opportunities within the Diabetes Devices and Therapeutics sector. Key highlights of the report include: Global Diabetes Landscape: With an estimated 537 million individuals worldwide affected by diabetes in 2021, this report explores the increasing prevalence and the significant health and economic burden it poses. Technological Advancements: The adoption of Continuous Glucose Monitoring (CGM) devices has seen a rapid rise, with the global user base increasing from 270,000 in 2017 to 1.7 million in 2022. In addition, tubeless insulin pumps are gaining traction due to their advantages, such as better glycemic control and improved patient quality of life. Innovative Therapies: The report sheds light on non-insulin treatments for diabetes, including exciting partnerships like the one between Wanbang Biopharmaceuticals and Sirona Biochem, as well as advancements in closed-loop systems and artificial pancreas technology. Pharmacotherapeutics: Discover the potential of SGLT2 inhibitors and the development of novel drug molecules like resveratrol, which show promise in improving diabetes management. Future of Diabetes Care: The report looks ahead to the future of diabetes management, discussing cutting-edge technologies like continuous glucose monitoring devices, artificial pancreas systems, gene therapy, and regenerative medicine approaches. Machine learning and big data analytics also play a pivotal role in early diagnosis and treatment. Investors, entrepreneurs, and managers can explore the advantages and limitations of each device and therapy, discuss the challenges associated with their use, and gain a panoramic view of emerging diabetes devices and technologies, as well as novel therapeutics that are currently being designed and developed. As diabetes continues to impact millions worldwide, our report is your gateway to understanding the rapidly evolving landscape of diabetes care. It provides a comprehensive overview of diabetes devices and therapeutics, highlighting their impact on diabetes management and patient outcomes, and emphasizing the need for ongoing research and innovation in this field. For those looking to invest in a thriving market, the report is the definitive resource. Don't miss out on the opportunities that the diabetes care industry has to offer. Get your copy of "Global Diabetes Devices and Therapeutics Business Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update" today and stay ahead of the curve. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

For more than a year, Sirona has said it was in discussions with companies that could license its diabetes med as a treatment for animals. Sirona is not beating around the bush: the company has had a difficult time selling its diabetes med and is now “less confident” it will score a licensing deal.  The candid about-face came in a corporate update Thursday, with the Canadian biotech saying that efforts to find a partner for TFC-039 have been “notably slow primarily due to the challenges in obtaining the clinical data held by our external partner.”  That’s a not-so-subtle dig at Wanbang Biopharmaceuticals in China, which Sirona has maintained an on-again, off-again relationship with for years. Sirona first out-licensed China rights for TFC-039 to Wanbang in 2014 but the latter company stopped further development in 2021 after completing a phase 1 trial. The two companies inked a new global partnership a year later, in November 2022, though the terms of the deal were not spelled out. Sirona only pocketed $1.5 million in upfront and milestone payments from the first China-focused pact.  The med is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a class of metabolic medicines that’s churned out treatments like Johnson & Johnson’s Invokana and AstraZeneca and Bristol Myers Squibb’s Forxiga. Sirona says that while looking for someone to help take TFC-039 forward, it has made “significant new advancements in the field of SGLT2 inhibitors.” What those advancements were, exactly, the biotech didn’t say. Evidently, they’re enough that the company isn’t axing all work on the class, saying that they’ll advance the new discoveries that have been made.  According to the company's website, Sirona was in late-stage discussions with four “major interested parties” from the animal health sector. And it’s been in the process of securing a patent on a new indication that’s yet to be unveiled.  Sirona’s latest update today suggests a bleak outlook for the med, which is the company’s lead foray into the pharmaceutical business after Sirona initially established itself as a cosmetic company. The biotech is also testing anti-viral compounds in collaboration with the International Centre for Genetic Engineering and Biotechnology, a research outpost originally launched by the United Nations that’s been independent for almost 30 years. Sirona says results of those tests “are expected within the next two months.”